The Filing Desk

Cellectis

CLLS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CLLS · Last close · November 19, 2026
$0.98

Cellectis' revenue rose 75.8% to $73 million in fiscal 2025. Its operating margin was −45.3%, up from −143.5% a year earlier. Free cash flow was −$42 million, against $20 million a year earlier. The diluted share count rose 10.7%.

Cellectis S.A. Latest fiscal year ended December 31, 2025 20-F filed March 20, 2026 · 0001193125-26-116428 Updated
Revenue
$73M
75.8%
Operating margin
−45.3%
98.2 pts
Net income
−$68M
 
Free cash flow
−$42M
$20M a year earlier
Return on equity
−65.3%
31.2 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Cellectis is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

What Cellectis does

Cellectis is a French biotechnology company that edits genes to make experimental cancer treatments. Its main products in development are CAR T-cells: immune cells engineered to find and kill cancer cells. Most such treatments are made from each patient's own cells. Cellectis instead makes them from healthy donors' cells, so that one batch could treat many patients and be stored and shipped "off the shelf." It is focused on blood cancers such as leukemia and lymphoma, and it also works on gene therapies for inherited diseases. It has no approved products.

Its lead candidate, lasme-cel, began a pivotal mid-stage trial, the kind meant to support approval, in late 2025, and a second, eti-cel, is in an earlier trial. The company also licenses its gene-editing tools, called TALEN, to other companies, among them AstraZeneca, Allogene and Iovance, which develop their own treatments and can owe Cellectis payments. AstraZeneca also became a shareholder, making an initial equity investment of $80 million in 2023.

Cellectis makes its own products for trials, at a plant in Raleigh, North Carolina, and a facility in Paris that makes raw and starting materials. At the end of 2025 it had 186 employees working in research and development. An arbitration with Servier ended part of a license for an older treatment in December 2025.

Its biggest risks, as it describes them

  • It has lost money in every period since it started and may need to raise more money, which may not be available.
  • Gene editing is still a new technology, which makes the time and cost of winning approval hard to predict.
  • Its treatments may cause serious side effects, as other CAR T-cell therapies have, which could halt their development.
  • Making its treatments is complex, and it needs a steady supply of immune cells from healthy donors.
  • Its licensing deals with other drug companies may not advance or succeed.
From Cellectis's annual report on Form 20-F, filed March 20, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Cellectis lost money in fiscal 2025: a net loss of $68 million.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1869313714362
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−281.2x−241.7x−2.4x−2.8x−0.7x
Current ratio4.6x2.5x———
Quick ratio4.6x2.5x———
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−3,515.8%5,446.5%18.5%
Altman Z''———
Accruals ratio−25.6%−16.6%−8.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rose———
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Cellectis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CellectisFY2575.8%−45.3%−57.2%———
CompugenFY25161.1%43.0%43.0%———Compare
Bicycle TherapeuticsFY25105.8%−340.4%−347.2%———Compare
Recursion PharmaceuticalsFY2526.9%−867.9%−506.5%−117.2%—4Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue4525131551301914273
Revenue growth−19.8%−43.8%−49.5%19.3%236.1%−40.6%−36.8%−96.1%5,397.4%75.8%
Gross profit—2310449281704273
Research and development787977927711898889094
Operating income−67−93−105−124−42−104−90−97−60−33
Net income−67−99−79−102−81−114−106−101−37−68
Diluted EPS (US$)−1.91−2.78−1.93−2.41−1.91−2.55−2.33−1.77−0.41−0.67
Diluted shares (millions)353641424245465791100
Cash flow
Cash from operations−33−52−68−69−80−105−87−2523−39
Capital expenditure14251344182132
Free cash flow−46−55−73−82−124−123−90−2620−42
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation5950372710126536
Balance sheet at fiscal year end
Cash and short-term investments2552564523402411869313714362
Debt incl. finance leases——————————
Total assets331333501468470382261334384325
Total liabilities584951112161146135250252249
Shareholders' equity2732654093152842211188513176
Margins and ratios
Gross margin—89.6%78.5%25.0%96.2%93.9%90.8%2.4%100.0%100.0%
Operating margin−150.2%−367.8%−825.5%−813.4%−82.9%−341.0%−467.7%−12,887.7%−143.5%−45.3%
Net margin−150.1%−394.5%−618.1%−672.1%−158.8%−376.3%−553.6%−13,385.3%−88.6%−92.7%
Free cash flow margin−103.6%−217.2%−572.2%−540.2%−243.5%−405.7%−468.8%−3,419.7%49.2%−57.2%
Rule of 40 (growth + FCF margin)−123.4%−261.0%−621.7%−520.9%−7.4%−446.2%−505.6%−3,515.8%5,446.5%18.5%
Return on capital——————————
Return on equity−24.1%−37.0%−23.4%−28.2%−27.1%−45.2%−62.6%−99.7%−34.1%−65.3%
Return on assets−19.1%−29.9%−18.9%−21.1%−17.3%−26.8%−33.0%−33.9%−10.2%−19.1%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cellectis' Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cellectis.